Curis is an oncology-focused companyseeking to develop and commercialize next generation targeted drug candidates for cancer treatment. Erivedge® is the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma and is being commercialized and developed by Roche and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Curis is also developing its pipeline of proprietary targeted cancer drug candidates, including CUDC-427, a small molecule antagonist of IAP proteins; CUDC-907, a dual PI3K and HDAC inhibitor; and CUDC-101, an EGFR/Her2 and HDAC inhibitor. For more information, visit Curis' website at www.curis.com.
Curis is developing several proprietary clinical-stage small molecules in testing for various cancers, including antagonist of IAP proteins CUDC-427, dual PI3K and HDAC inhibitor CUDC-907 and EGFR/Her2 and HDAC inhibitor CUDC-101.
Curis’ collaborator Genentech (Roche) is commercializing Hedgehog pathway inhibitor Erivedge® (vismodegib) in the U.S. for advanced basal cell carcinoma. Roche continues to seek approvals for Erivedge in several different territories in this lead indication and is also testing Erivedge in less severe forms of BCC. Several additional clinical studies are ongoing under collaborations between Genentech and the National Cancer Institute and independent study investigators.
Curis licensee Debiopharm is also conducting clinical studies on HSP90 inhibitor Debio 0932 in patients with advanced lung cancer and expects to initiate additional testing in patients with renal cell carcinoma during the second half of 2013.
Senior Research Associate - Translational Biomarker & Pre-Clinical:
Curis is seeking a self-motivated senior research associate to join an established preclinical and translational biomarker group working on efficacy and PK/PD relationship studies to support clinical development. The position requires solid background in in vivo pharmacology, especially in oncology animal model development, hands-on experience in biomarker identification, and broad knowledge in cancer signaling pathways. Experience with subcutaneous xenograft models and Western blot analysis is required. Expertise in orthotopic and patient derived xenograft models and IHC preferred. The ideal candidate will be expected to perform experiments independently with limited supervision, be able to analyze and interpret data. He or she will be flexible to accommodate rapidly changing priorities and meet project deadlines, and work efficiently in a multidisciplinary team setting.
BS with a minimum of 8 years of experience, or MS with a minimum of 4 years of experience in animal research. Previous industry experience is strongly preferred.
Expertise in oncology model development, especially xenograft models.
Hands-on experience in compound preparing, rodent handling, dosing (po., iv., ip., im. ,sc.) bleeding, tissue collection, small animal surgery, etc.
Proficient in mammalian cell culture.
In-depth experience in molecular biology such as transfection, qPCR, Western blotting, etc.
Excellent documentation, communication, and interpersonal skills.
Please send CV with job code (RAIV200) to:
Human Resources, Curis, Inc.
CMC Scientist - Development:
Curis is seeking an energetic, motivated Scientist to participate in the key functions of chemistry, manufacturing and controls (CMC), ensuring the timely delivery of drug products to support the Company’s clinical studies. Reporting to the Director, CMC, this individual will be expected to work closely with other members of the clinical development, pre-clinical, and chemistry groups within the Company. The candidate should be familiar with both the technical side of drug product manufacturing and formulations, as well as the requirements for regulatory filings in the USA and Europe. The selected candidate will be working in a multidisciplinary environment and will be expected to assist with all aspects of the manufacturing and distribution process.
Drives formulation development, optimization, and production using rational design and data analysis;
Executes technical transfers, scale up and clinical manufacture at CMOs;
Writes and reviews technical reports, including regulatory filing source documents;
Prepares and presents experimental conclusions at various technical meetings;
Supervises formulation development activities at CRO/CMO and academic institutions and collaborators;
Assists with clinical trial material packaging, labeling and distribution.
A Bachelor’s Degree or Master’s degree with a life science concentration in chemistry, pharmaceutics or engineering is required. 5+ years (with B.S.), or 2+ years (with M.S.) pharmaceutical industry experience is required.
Preferred Knowledge, Skills and Abilities:
Experience working with small molecule new chemical entities (NCEs) for oral delivery.
Experience with formulation development for poorly soluble compounds.
Experience developing formulations to support toxicology studies.
Experience managing the scale-up and manufacture of solid oral dosage forms.
GLP or GMP experience.
The successful candidate will be flexible and creative to meet the developing needs of the programs, while at the same time is diligent and focused on details. The candidate should have the ability to work effectively and comfortably in a multi-disciplinary team, under defined timelines. Excellent teamwork, verbal and written communication skills are essential.
Please send CV with job code (CMCS330) to:
Human Resources, Curis, Inc.
Qualified candidates should submit their CVs, with job code, via email to email@example.com, via fax to 617-503-6501, or mail to:
No phone calls please.
Curis, Inc. is an Equal Opportunity Employer.